BUDZ 最新10-Q变化
将 BUDZ 最新的定期申报(10-K/10-Q)与上一份同类型申报逐章节对比:每个章节新增/删除的段落数与原文摘录。全部为确定性文本对比——无相似度评分、无方向判断、非投资建议。
对比:10-Q · 2026-08-14 与上一份 10-Q · 2026-05-15
| 章节 | 结果 | 新增 | 删除 | 微调 | 未变 |
|---|---|---|---|---|---|
| 管理层讨论与分析 | 文字有新增/删除 | +13 | −5 | ~54 | 120 |
| 市场风险(第3项) | 文字有新增/删除 | +13 | −5 | ~54 | 119 |
| 控制与程序 | 文字有新增/删除 | +13 | −5 | ~54 | 119 |
| 法律诉讼 | 文字有新增/删除 | +13 | −5 | ~54 | 119 |
| 风险因素 | 部分风险因素更新 | +13 | −5 | ~54 | 119 |
| 其他信息 | 文字有新增/删除 | +13 | −5 | ~54 | 119 |
计数单位为段落;"新增/删除"指相对上一份文件新增/删除的文字,不含方向或好坏判断。
代表性摘录
每个章节最多 5 条、每条约 300 字符的原文摘录,直接来自两份 SEC 文件。
管理层讨论与分析
相对上期新增的文字 · 来源:10-Q · 2026-08-14
Six Months Ended June 30, 2026 Compared to Six Months Ended June 30, 2025
Foreign currency translation gain on dissolution of subsidiary
Our comprehensive net loss decreased by $267,492, from $(546,884) to $(279,392), from the six months ended June 30, 2026, compared to the six months ended June 30, 2025. Our net operating loss decreased by $273,912 from $(528,782) to $(254,870) for the same period. The decrease in our comprehensive …
We have not had any revenues since our inception. Once we have sufficient funding, we plan to research and possibly enter the hemp and infused beverage industry through our newly acquired property in New York, and conduct Sangre’s Cannabis Genomic Study and process those result. In the long-term we …
General and administrative expenses decreased by $304,757, from $447,320 for the six months ended June 30, 2025, to $142,563 for the six months ended June 30, 2026, primarily due to decreases in our consulting services and salary.
相对上期删除的文字 · 来源:10-Q · 2026-05-15
During the three months ended March 31, 2026, because of our operating losses, we did not generate positive operating cash flows. Our cash on hand as of March 31, 2026 was $1,795 and our monthly cash flow burn rate was approximately $12,000. We currently do not believe we will be able to satisfy our…
Our cash, current assets, total assets, current liabilities, and total liabilities as of March 31, 2026, and December 31, 2025, respectively, are as follows:
Our total assets decreased by $44,193 as of March 31, 2026 as compared to December 31, 2025. The decrease in our total assets between the two periods was attributed primarily to decreases in cash.
Our current liabilities and total liabilities increased by $104,973, as of March 31, 2026, as compared to December 31, 2025. This increase was primarily due to increases in accounts payable, related parties, and accrued officer compensation.
During the period ended March 31, 2026, 880,000 shares of common stocks valued at $26,400 were issued for the services.
市场风险(第3项)
相对上期新增的文字 · 来源:10-Q · 2026-08-14
Six Months Ended June 30, 2026 Compared to Six Months Ended June 30, 2025
Foreign currency translation gain on dissolution of subsidiary
Our comprehensive net loss decreased by $267,492, from $(546,884) to $(279,392), from the six months ended June 30, 2026, compared to the six months ended June 30, 2025. Our net operating loss decreased by $273,912 from $(528,782) to $(254,870) for the same period. The decrease in our comprehensive …
We have not had any revenues since our inception. Once we have sufficient funding, we plan to research and possibly enter the hemp and infused beverage industry through our newly acquired property in New York, and conduct Sangre’s Cannabis Genomic Study and process those result. In the long-term we …
General and administrative expenses decreased by $304,757, from $447,320 for the six months ended June 30, 2025, to $142,563 for the six months ended June 30, 2026, primarily due to decreases in our consulting services and salary.
相对上期删除的文字 · 来源:10-Q · 2026-05-15
During the three months ended March 31, 2026, because of our operating losses, we did not generate positive operating cash flows. Our cash on hand as of March 31, 2026 was $1,795 and our monthly cash flow burn rate was approximately $12,000. We currently do not believe we will be able to satisfy our…
Our cash, current assets, total assets, current liabilities, and total liabilities as of March 31, 2026, and December 31, 2025, respectively, are as follows:
Our total assets decreased by $44,193 as of March 31, 2026 as compared to December 31, 2025. The decrease in our total assets between the two periods was attributed primarily to decreases in cash.
Our current liabilities and total liabilities increased by $104,973, as of March 31, 2026, as compared to December 31, 2025. This increase was primarily due to increases in accounts payable, related parties, and accrued officer compensation.
During the period ended March 31, 2026, 880,000 shares of common stocks valued at $26,400 were issued for the services.
控制与程序
相对上期新增的文字 · 来源:10-Q · 2026-08-14
Six Months Ended June 30, 2026 Compared to Six Months Ended June 30, 2025
Foreign currency translation gain on dissolution of subsidiary
Our comprehensive net loss decreased by $267,492, from $(546,884) to $(279,392), from the six months ended June 30, 2026, compared to the six months ended June 30, 2025. Our net operating loss decreased by $273,912 from $(528,782) to $(254,870) for the same period. The decrease in our comprehensive …
We have not had any revenues since our inception. Once we have sufficient funding, we plan to research and possibly enter the hemp and infused beverage industry through our newly acquired property in New York, and conduct Sangre’s Cannabis Genomic Study and process those result. In the long-term we …
General and administrative expenses decreased by $304,757, from $447,320 for the six months ended June 30, 2025, to $142,563 for the six months ended June 30, 2026, primarily due to decreases in our consulting services and salary.
相对上期删除的文字 · 来源:10-Q · 2026-05-15
During the three months ended March 31, 2026, because of our operating losses, we did not generate positive operating cash flows. Our cash on hand as of March 31, 2026 was $1,795 and our monthly cash flow burn rate was approximately $12,000. We currently do not believe we will be able to satisfy our…
Our cash, current assets, total assets, current liabilities, and total liabilities as of March 31, 2026, and December 31, 2025, respectively, are as follows:
Our total assets decreased by $44,193 as of March 31, 2026 as compared to December 31, 2025. The decrease in our total assets between the two periods was attributed primarily to decreases in cash.
Our current liabilities and total liabilities increased by $104,973, as of March 31, 2026, as compared to December 31, 2025. This increase was primarily due to increases in accounts payable, related parties, and accrued officer compensation.
During the period ended March 31, 2026, 880,000 shares of common stocks valued at $26,400 were issued for the services.
法律诉讼
相对上期新增的文字 · 来源:10-Q · 2026-08-14
Six Months Ended June 30, 2026 Compared to Six Months Ended June 30, 2025
Foreign currency translation gain on dissolution of subsidiary
Our comprehensive net loss decreased by $267,492, from $(546,884) to $(279,392), from the six months ended June 30, 2026, compared to the six months ended June 30, 2025. Our net operating loss decreased by $273,912 from $(528,782) to $(254,870) for the same period. The decrease in our comprehensive …
We have not had any revenues since our inception. Once we have sufficient funding, we plan to research and possibly enter the hemp and infused beverage industry through our newly acquired property in New York, and conduct Sangre’s Cannabis Genomic Study and process those result. In the long-term we …
General and administrative expenses decreased by $304,757, from $447,320 for the six months ended June 30, 2025, to $142,563 for the six months ended June 30, 2026, primarily due to decreases in our consulting services and salary.
相对上期删除的文字 · 来源:10-Q · 2026-05-15
During the three months ended March 31, 2026, because of our operating losses, we did not generate positive operating cash flows. Our cash on hand as of March 31, 2026 was $1,795 and our monthly cash flow burn rate was approximately $12,000. We currently do not believe we will be able to satisfy our…
Our cash, current assets, total assets, current liabilities, and total liabilities as of March 31, 2026, and December 31, 2025, respectively, are as follows:
Our total assets decreased by $44,193 as of March 31, 2026 as compared to December 31, 2025. The decrease in our total assets between the two periods was attributed primarily to decreases in cash.
Our current liabilities and total liabilities increased by $104,973, as of March 31, 2026, as compared to December 31, 2025. This increase was primarily due to increases in accounts payable, related parties, and accrued officer compensation.
During the period ended March 31, 2026, 880,000 shares of common stocks valued at $26,400 were issued for the services.
风险因素
相对上期新增的文字 · 来源:10-Q · 2026-08-14
Six Months Ended June 30, 2026 Compared to Six Months Ended June 30, 2025
Foreign currency translation gain on dissolution of subsidiary
Our comprehensive net loss decreased by $267,492, from $(546,884) to $(279,392), from the six months ended June 30, 2026, compared to the six months ended June 30, 2025. Our net operating loss decreased by $273,912 from $(528,782) to $(254,870) for the same period. The decrease in our comprehensive …
We have not had any revenues since our inception. Once we have sufficient funding, we plan to research and possibly enter the hemp and infused beverage industry through our newly acquired property in New York, and conduct Sangre’s Cannabis Genomic Study and process those result. In the long-term we …
General and administrative expenses decreased by $304,757, from $447,320 for the six months ended June 30, 2025, to $142,563 for the six months ended June 30, 2026, primarily due to decreases in our consulting services and salary.
相对上期删除的文字 · 来源:10-Q · 2026-05-15
During the three months ended March 31, 2026, because of our operating losses, we did not generate positive operating cash flows. Our cash on hand as of March 31, 2026 was $1,795 and our monthly cash flow burn rate was approximately $12,000. We currently do not believe we will be able to satisfy our…
Our cash, current assets, total assets, current liabilities, and total liabilities as of March 31, 2026, and December 31, 2025, respectively, are as follows:
Our total assets decreased by $44,193 as of March 31, 2026 as compared to December 31, 2025. The decrease in our total assets between the two periods was attributed primarily to decreases in cash.
Our current liabilities and total liabilities increased by $104,973, as of March 31, 2026, as compared to December 31, 2025. This increase was primarily due to increases in accounts payable, related parties, and accrued officer compensation.
During the period ended March 31, 2026, 880,000 shares of common stocks valued at $26,400 were issued for the services.
其他信息
相对上期新增的文字 · 来源:10-Q · 2026-08-14
Six Months Ended June 30, 2026 Compared to Six Months Ended June 30, 2025
Foreign currency translation gain on dissolution of subsidiary
Our comprehensive net loss decreased by $267,492, from $(546,884) to $(279,392), from the six months ended June 30, 2026, compared to the six months ended June 30, 2025. Our net operating loss decreased by $273,912 from $(528,782) to $(254,870) for the same period. The decrease in our comprehensive …
We have not had any revenues since our inception. Once we have sufficient funding, we plan to research and possibly enter the hemp and infused beverage industry through our newly acquired property in New York, and conduct Sangre’s Cannabis Genomic Study and process those result. In the long-term we …
General and administrative expenses decreased by $304,757, from $447,320 for the six months ended June 30, 2025, to $142,563 for the six months ended June 30, 2026, primarily due to decreases in our consulting services and salary.
相对上期删除的文字 · 来源:10-Q · 2026-05-15
During the three months ended March 31, 2026, because of our operating losses, we did not generate positive operating cash flows. Our cash on hand as of March 31, 2026 was $1,795 and our monthly cash flow burn rate was approximately $12,000. We currently do not believe we will be able to satisfy our…
Our cash, current assets, total assets, current liabilities, and total liabilities as of March 31, 2026, and December 31, 2025, respectively, are as follows:
Our total assets decreased by $44,193 as of March 31, 2026 as compared to December 31, 2025. The decrease in our total assets between the two periods was attributed primarily to decreases in cash.
Our current liabilities and total liabilities increased by $104,973, as of March 31, 2026, as compared to December 31, 2025. This increase was primarily due to increases in accounts payable, related parties, and accrued officer compensation.
During the period ended March 31, 2026, 880,000 shares of common stocks valued at $26,400 were issued for the services.
如何读 10-Q 的风险因素(第 1A 项)
10-Q 的风险因素章节有三种常见形态,本页按其一分类展示:
- 指向(pointer) — 公司仅声明"无重大变化"并指向年度 10-K 的完整风险因素;本季没有自己的风险文本可对比。
- 部分更新(partial) — 公司写明"除下述外无重大变化",只更新部分风险;摘录展示的正是本季新增的内容。
- 全文重述(restated) — 本季重新给出完整风险因素。若上一季只是"指向",则无法逐段对比,本页会将其标为"本季全文重述"。
这只是对文件结构的客观描述,不构成对风险高低的判断。
数据来自 SEC EDGAR 两份申报文件的文本级对比 · 确定性计算(无 AI 生成内容)· 仅供参考 · 非投资建议